Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $79
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $56 to $79.
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $56 to $79.